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Optimizing Long-Term Outcomes After TAVR*Dhruv S. Kazi, MD, MSC, MSyzNothing can stop an idea whose time has come.
—Victor Hugo (1)SEE PAGE 2605P ercutaneous replacement or repair of heartvalves have been some of the most exciting in-novations in the ﬁeld of interventional cardi-
ology in the past decade. Since the early animal
experiments by Henning-Rud Andersen in 1992 (2)
and the ﬁrst-in-human deployment by Alain Cribier
in 2002 (3), transcatheter aortic valve replacement
(TAVR) has moved from being an investigational pro-
cedure reserved for patients without surgical options
to an effective and, when performed through transfe-
moral access, a cost-effective alternative in patients
at high risk for surgical complications (4). Newer gen-
erations of the devices have lower proﬁle delivery
systems, incorporate adaptable seals to prevent para-
valvular regurgitation, and may be repositionable to
facilitate accurate deployment (5). Accumulating evi-
dence of efﬁcacy, durability, and safety has led to
calls for expanding the indications for TAVR, and
several ongoing trials are examining outcomes in
intermediate-risk patients (6). With increasing de-
mand from an aging population as well as a rapidly
improving supply of centers offering the procedure,
the number of TAVRs performed is projected to rise
exponentially over the coming decade.
The dissemination of a device or surgical proce-
dure that was previously only offered only in research
settings involves 3 phases. The primary concern in
the ﬁrst phase is ensuring that practitioners in the*Editorials published in the Journal of the American College of Cardiology
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pioneering operators at high-volume academic cen-
ters. This can be challenging because of the learning
curve associated with complex procedures and a
strong correlation between higher procedure volumes
and better clinical outcomes. The second phase of
dissemination relates to the increasing real-world
experience with the device, which yields additional
insights into its effectiveness and durability and may
lead to the recognition of rare or delayed complica-
tions that were not observed in the initial trials
(which typically have fewer patients and shorter
follow-up periods). This eventually results in im-
proved patient selection, reﬁnements in the tech-
nology or procedure, or changes in the protocol for
post-intervention management. The third and ﬁnal
stage of technology dissemination is maturation and
widespread adoption, when the focus shifts to
decreasing practice variability, and controlling costs.Initial post-approval data from the United States
suggest that TAVR has sailed smoothly past the ﬁrst
phase. Data from nearly 250 centers participating
in the controlled rollout of TAVR have shown that
the community experience mirrors the ﬁndings of
randomized clinical trials (7). This initial success is
likely the result of intense site training, close su-
pervision of early adopters by the manufacturer,
and a team-based approach to care delivery. The
work by Généreux et al. (8) in this issue of the
Journal is a striking reminder that TAVR is now well
into in the second phase of technology dissemina-
tion, in which careful analysis of the accumulating
evidence will yield valuable insights that should be
harnessed to optimize long-term outcomes.
The investigators examine the association between
major late bleeding complications (MLBCs) after
TAVR, deﬁned as major bleeding occurring between
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261730 days and 1 year after the procedure, and all-cause
mortality. The investigators collated a dataset of
2,401 patients who were treated with TAVR and sur-
vived to 30 days, including patients from PARTNER
(Placement of Aortic Transcatheter Valves) random-
ized trial cohorts A (high risk but operable, n ¼ 236)
and B (inoperable, n ¼ 164), and 2 continued-access
registries (n ¼ 1,911). During a median follow-up
period of 1 year, 142 patients (5.9%) experienced
MLBCs, on average approximately 4 months after the
initial procedure. The most frequent bleeding sources
were gastrointestinal (41%) and neurological (16%),
including falls resulting in traumatic intracranial
bleeds (6%). After adjusting for demographic, clinical,
and procedural characteristics, 4 factors predicted an
increased risk for MLBCs during follow-up: lower
baseline hemoglobin, increased left ventricular mass,
the presence of atrial ﬁbrillation (AF), and a moderate
to severe paravalvular leak. Compared with those
who did not experience MLBCs during follow-up,
patients who did were at increased risk for all-cause
death, death from cardiac causes, major stroke, re-
hospitalization, and the development of renal failure
requiring dialysis. After multivariate adjustment for
baseline, clinical, and procedural characteristics,
MLBCs were associated with nearly 4-fold risk for
all-cause mortality (adjusted hazard ratio: 3.83; 95%
conﬁdence interval: 2.62 to 5.61; p < 0.001). The
ﬁndings were consistent within subgroup analyses by
sex, age, and surgical risk.
When faced with novel experimental results, a
scientiﬁc mind asks 3 questions: 1) Are these results
real? 2) Is this association causal? 3) What are the
implications of these ﬁndings?
ARE THE FINDINGS REAL?
The interpretation of results from nonrandomized
data necessitates caution, primarily because of con-
cerns about residual confounding. Contemporary
statistical techniques perform well at adjusting
observed differences between the 2 groups, but un-
observed differences may bias the results. For in-
stance, if doctors systematically offer a surgical
procedure to their least frail patients, and in as much
as frailty is not perfectly captured by the variables
in the dataset, the procedure may appear to be
more effective than it actually is (9). Despite the
meticulous nature of this analysis, some concerns
about unobserved confounders remain. For instance,
in what appears to be a major oversight in the design
of the original studies, data about anticoagulant use
(a predictor of bleeding complications) were not
prospectively collected. The authors use AF as asurrogate for anticoagulation due to the high antico-
agulant use in older patients with hypertension and
valvular disease. However, AF is an imperfect surro-
gate for anticoagulation, and the analysis fails to -
account for patients taking anticoagulant agents for
other indications, such as thromboembolic disease.
Nevertheless, the strength of the association between
MLBCs and mortality (with a near quadrupling of the
hazard of death even after multivariate adjustment)
would suggest that the association is real.
IS THE ASSOCIATION CAUSAL?
Another concern with observational analyses is that
correlation does not imply causation. Does bleeding
increase the risk for mortality, or are high-risk pa-
tients more likely to bleed? Evidence from other set-
tings suggests that the association between bleeding
and long-term mortality may be causal, mediated by
the physiologic effect of the bleed itself and subse-
quent interventions, such as transfusion of blood
products (10) or cessation of antiplatelet agents or
anticoagulant agents. In the case of observational
studies, the plausibility of the ﬁndings may also make
a case for a causal association. Of the 4 factors that
predicted post-TAVR MLBCs, lower baseline hemo-
globin and the presence of AF or atrial ﬂutter (as a
marker of anticoagulant use) are intuitive. Also,
increased left ventricular mass may be a marker of
end-organ damage from long-standing hypertension.
The association between moderate to severe para-
valvular leak and MLBCs is novel and interesting: the
investigators hypothesize that this may represent
an acquired thrombophilia from turbulence-induced
cleavage of proaggregation proteins. If future in-
vestigations conﬁrm the association between para-
valvular regurgitation and MLBCs, the underlying
mechanism and strategies to address it deserve fur-
ther investigation. Deﬁnitive evidence of causation,
however, will only be available if future random-
ized trials to reduce MLBCs demonstrate improved
survival.
WHAT ARE THE IMPLICATIONS?
Finally, if these ﬁndings are reproduced in other co-
horts, the observed association between MLBCs and
long-term mortality after TAVR has important clinical
implications. Since the introduction of TAVR, an
intense focus on technological and procedural im-
provements has substantially reduced peripro
cedural bleeding. These ﬁndings argue that bleed
reduction strategies must also be extended to the
ﬁrst year post-procedure. In the future, nested clin-
ical trials or well-designed observational analyses
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tion and the effectiveness of pre- or post-procedure
bleed reduction interventions on long-term out-
comes after TAVR. Following on the impressive
reductions in procedural complications, the focus
must shift to improving long-term outcomes. Small
reﬁnements in the TAVR protocol could yield valu-
able clinical and economic dividends by reducing
delayed complications.
There is palpable excitement among patients and
their cardiologists for safe and effective transcatheter
valve repair and replacement. This technology rep-
resents a disruptive innovation that has changed theway we deliver care for advanced valvular disease,
and its explosive growth argues that this is indeed an
idea whose time has come. But as Généreux et al. (8)
remind us, even as we embrace the technology,
careful attention to accumulating evidence offers a
unique opportunity to continue to optimize long-
term outcomes after TAVR.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Dhruv S. Kazi, San Francisco General Hospital,
Division of Cardiology, 1001 Potrero Avenue, Room
5G1, San Francisco, California 94110. E-mail: kazi@
ucsf.edu; Twitter: http://twitter.com/kardiologykazi.RE F E RENCE S1. Hugo V. Histoire d’un Crime. 1877.
2. Andersen HR, Knudsen LL, Hasenkam JM.
Transluminal implantation of artiﬁcial heart
valves. Description of a new expandable aortic
valve and initial results with implantation by
catheter technique in closed chest pigs. Eur Heart
J 1992;13:704–8.
3. Cribier A, Eltchaninoff H, Bash A, et al. Percu-
taneous transcatheter implantation of an aortic
valve prosthesis for calciﬁc aortic stenosis: ﬁrst
human case description. Circulation 2002;106:
3006–8.
4. Reynolds MR, Magnuson EA, Lei Y, et al. Cost-
effectiveness of transcatheter aortic valve
replacement compared with surgical aortic valve
replacement in high-risk patients with severeaortic stenosis: results of the PARTNER (Placement
of Aortic Transcatheter Valves) trial (cohort A).
J Am Coll Cardiol 2012;60:2683–92.
5. Sorajja P, Pedersen W. Next-generation trans-
catheter aortic valve replacement: evolution of a
revolution. J Am Coll Cardiol 2014;64:1349–51.
6. Grube E, Sinning JM, Vahanian A. The year in
cardiology 2013: valvular heart disease (focus on
catheter-based interventions). Eur Heart J 2014;
35:490–5.
7. Mack MJ, Brennan JM, Brindis R, et al. Outcomes
following transcatheter aortic valve replacement
in the United States. JAMA 2013;310:2069–77.
8. Généreux P, Cohen DJ, Mack M, et al.
Incidence, predictors, and prognostic impact oflate bleeding complications after transcatheter
aortic valve replacement. J Am Coll Cardiol 2014;
64:2605–15.
9. Farzaneh-Far R, Bolger AF. Surgical timing in
infectious endocarditis: wrestling with the
unrandomized. Circulation 2010;121:960–2.
10. Nuis RJ, Rodes-Cabau J, Sinning JM, et al.
Blood transfusion and the risk of acute kidney
injury after transcatheter aortic valve implanta-
tion. Circ Cardiovasc Interv 2012;5:680–8.KEY WORDS bleeding, TAVI, technology
dissemination, transcatheter aortic valve
replacement
